A practical reference on Freeze-thaw: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-17. Anything still debated is marked as such rather than presented as settled.
Other chromatographic modes provide complementary information that reverse-phase separation may not capture. Ion-exchange chromatography separates peptides by net charge and can resolve deamidated, oxidized, or truncated variants that co-elute under hydrophobic conditions. Size-exclusion chromatography detects aggregates and higher-order oligomers, which are often invisible in reverse-phase assays. Chiral chromatography can quantify D-amino acid epimers when stereochemical purity matters. Because each mode uses a different separation principle, a single purity number from one method cannot describe all possible impurities.
Interpreting chromatographic purity requires attention to detection limits and response factors. Peptides without aromatic residues may absorb weakly at 280 nm, so 214 nm is often preferred, but mobile-phase additives and solvents also absorb at low wavelengths. Co-eluting impurities with different molar absorptivities can produce area percentages that differ from mass percentages. Integration parameters, peak tailing, and baseline choice further affect reported values. For these reasons, method details belong alongside any purity figure, and orthogonal methods are needed to confirm identity and impurity profiles.
Peptide purity specifications describe the minimum acceptable result from a defined test. A certificate of analysis may list HPLC purity, mass spectrometry identity, appearance, and counterion content. Specifications are method-dependent, so a value obtained with one gradient or wavelength may differ from another. For research use, common thresholds include 95% and 98% by RP-HPLC, but the appropriate limit depends on the application. The specification should always name the analytical method and acceptance criterion.
Quality control includes system suitability, blank injections, and reference standards. System suitability checks column performance and retention time reproducibility, while blank runs detect carryover or mobile-phase contaminants. Reference standards help calibrate retention time and detector response. Without these controls, a purity value is difficult to compare across laboratories or over time. Documentation of instrument settings and integration parameters is also part of quality control, and acceptance criteria should be set before samples are analyzed.
Impurity profiles can include deletion peptides, oxidized forms, truncated sequences, and residual solvents. Some impurities arise during synthesis, cleavage, or purification, while others form during storage. Purity testing often focuses on peptide-related impurities, whereas residual solvents and counterions require separate assays. The significance of a given impurity depends on its amount and properties, which may not be established for a research peptide. Reporting an impurity profile is more informative than reporting a single purity number.
| Property | Value | Notes |
|---|---|---|
| Typical primary method | Reverse-phase HPLC | Separates mainly by hydrophobicity |
| Typical detection wavelength | 214 nm | Peptide bond absorbance; low UV |
| Common ion-pairing agent | Trifluoroacetic acid | Improves peak shape in acidic mobile phase |
| Typical purity metric | Area percent of main peak | Depends on detection and integration |
| Complementary method | Ion-exchange chromatography | Resolves charge variants |
Purity results are only meaningful when linked to a defined sample and method. A certificate of analysis typically lists the analytical technique, column type, gradient, detection wavelength, and integration parameters. It may also report mass confirmation, water content, and counterion composition. For research peptides, laboratories often request the raw chromatogram rather than only a summary percentage. This allows independent review of baseline, peak shape, and any unresolved shoulders that might be missed by a single number.
Stability testing examines how purity changes under controlled conditions. Samples are stored at defined temperatures, such as -20 °C or -80 °C, and analyzed at intervals. Lyophilized powders are generally more stable than solutions because water promotes hydrolysis and aggregation. Repeated freeze-thaw cycles can also degrade peptides, especially those with oxidation-prone residues. Accelerated studies at elevated temperature provide useful comparisons, but they do not always predict long-term behavior at lower temperatures.
Handling practices influence measured purity. Peptides may adsorb to plastic or glass surfaces, particularly when hydrophobic or positively charged. Weighing hygroscopic powders can introduce water and alter concentration. Dissolving in appropriate solvents and using low-binding tubes can reduce losses. Each laboratory should validate its own procedures because recovery and stability vary with peptide sequence, formulation, and container material. Open questions remain about how best to standardize stability reporting across different peptide classes.
Quality control for peptides begins with a documented specification that states the required purity, identity, and appearance. Suppliers often release research-grade material at 95% or greater by HPLC area, but this threshold is not universal. A certificate of analysis typically records the lot number, sequence, test methods, and measured values. The document allows a user to compare batches and to trace deviations. Specifications should match the intended use rather than a generic label.
Storage and handling conditions affect both peptide stability and the accuracy of later purity tests. Lyophilized powders are commonly kept desiccated at -20 °C or below, while reconstituted solutions require a defined buffer, pH, and temperature range. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis over time. Each cycle may alter the chromatogram and complicate comparison with earlier results. Stability data, when available, should guide handling intervals and solvent choice.
Because nickel is resistant to corrosion, it was occasionally used as a substitute for decorative silver. Nickel was also occasionally used in some countries after 1859 as a cheap coinage metal (see above), but in the later years of the 20th century, it was replaced by cheaper stainless steel (i.e., iron) alloys, except in the United States and Canada. Nickel is an excellent alloying agent for certain precious metals and is used in the fire assay as a collector of platinum group elements (PGE). As such, nickel can fully collect all six PGEs from ores, and can partially collect gold. High-throughput nickel mines may also do PGE recovery (mainly platinum and palladium); examples are Norilsk, Russia and the Sudbury Basin, Canada. Nickel foam or nickel mesh is used in gas diffusion electrodes for alkaline fuel cells. Nickel and its alloys are often used as catalysts for hydrogenation reactions. Raney nickel, a finely divided nickel-aluminium alloy, is one common form, though related catalysts are also used, including Raney-type catalysts. Nickel is naturally magnetostrictive: in the presence of a magnetic field, the material undergoes a small change in length. The magnetostriction of nickel is on the order of 50 ppm and is negative, indicating that it contracts. Nickel is used as a binder in the cemented tungsten carbide or hardmetal industry and used in proportions of 6% to 12% by weight. Nickel makes the tungsten carbide magnetic and adds corrosion-resistance to the cemented parts, though the hardness is less than those with cobalt binder.
=== Oxford debate walkout, 2013 === On 20 February 2013, Galloway walked out of a publicised debate when he found out that his opponent had Israeli citizenship. The debate, hosted by Oxford University's Christ Church, was on the topic "Israel should withdraw immediately from the West Bank". Galloway interrupted his opponent, Eylon Levy, a third-year PPE student, to ask whether he was an Israeli. When Levy acknowledged his joint British–Israeli nationality, Galloway stood up and stated "I don't recognise Israel and I don't debate with Israelis" and left the meeting. Explaining his actions on his Facebook page, Galloway wrote:
== History == in 1957 Lundberg reported on a group of patients with a condition he named myalgia cruris epidemica, seemingly the first description of BACM. Other terms later used include influenza-associated myositis, viral myositis, acute myositis Middleton and colleagues reported on BACM as severe myositis after influenza in 1970. Viral myositis may occur also in later years.
Sources: en.wikipedia.org
=== Active funds === A few actively managed investment funds have been created which target the megacap segment of the US stock market. They explicitly give their own definitions of the megacap segment when explaining their investment strategies. The Fidelity Mega Cap Stock Fund mutual fund (ticker symbol: FGRTX) defines megacaps as companies "whose market capitalization is similar to [that] of companies in the Russell Top 200 Index or the S&P 100 Index". As of December 31, 2025, the fund had 116 holdings. The Principal US Mega-Cap ETF (Nasdaq: USMC) defines megacaps as companies "with market capitalizations in the top 50th percentile of the S&P 500 Index". As of September 30, 2025, such companies had market caps ranging from $149.6 billion to $4.6 trillion. As of June 30, 2025, the fund had 27 holdings.
=== Brain growth === Neuroanatomical studies and the association between autism and teratogens strongly suggest that autism affects brain development soon after conception. This anomaly appears to start a cascade of pathological events in the brain that are significantly influenced by environmental factors. Just after birth, the brains of children with autism tend to grow faster than usual, followed by normal or relatively slower growth in childhood. It is unknown whether early brain overgrowth occurs in all children with autism. It appears to be most prominent in the frontal and temporal lobes, which are associated with higher cognitive specializations such as social cognition, and language development. Hypotheses for the cellular and molecular bases of pathological early overgrowth include an excess of neurons that causes local overconnectivity in key brain regions, and disturbed neuronal migration during early gestation.
== Premise == FBI agents Cooper Madsen and Jordan Bennett investigate a series of unexplained deaths among international supermodels. Their inquiry leads to the discovery of a sexually transmitted virus called "The Beauty," which grants physical attractiveness but carries fatal consequences. As they trace its origins, the agents uncover a connection to a powerful and secretive tech figure known as "The Corporation," who seeks to protect the drug and its global expansion. Pursued by a hired operative known as "The Assassin," the agents continue their investigation across multiple international cities amid the growing outbreak.
Sources: en.wikipedia.org
HPLC purity measures the relative area of the main peptide peak compared with all detected peaks under one set of separation and detection conditions. It is an operational value rather than an absolute mass fraction. Compounds that do not absorb at the detection wavelength or that co-elute with the main peak are not counted.
The peptide bond absorbs ultraviolet light near 214 nm, so this wavelength detects the backbone of most peptides regardless of aromatic content. It is more universal than 280 nm, which mainly detects tryptophan, tyrosine, and phenylalanine. Mobile-phase components can also absorb at 214 nm, so blank subtraction and method controls are important.
No single chromatographic method resolves all possible peptide impurities, because variants may differ in charge, size, hydrophobicity, or stereochemistry. Deamidated and oxidized forms may co-elute in reverse-phase systems, while aggregates require size-exclusion separation. Orthogonal methods and mass spectrometry are therefore used together for a fuller impurity profile.
It is a document reporting test results for a specific lot, often including appearance, HPLC purity, mass identity, and storage conditions. It should identify the analytical method and acceptance criteria. The certificate describes the tested sample, not necessarily every vial.